MedTrace Logo

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

NCT07645820 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2026-06-12

No results posted yet for this study

Summary

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.

Conditions

Interventions

DEVICE

Nevisense electrical impedance spectroscopy

The NevisenseGo device will collect skin measurements from people with atopic dermatitis (AD) to see if it can effectively predict a flare in disease.

Sponsors & Collaborators

  • SciBase AB

    collaborator OTHER

  • Castle Biosciences Incorporated

    lead INDUSTRY

Eligibility

Min Age
12 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-29
Primary Completion
2027-04-01
Completion
2027-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07645820 on ClinicalTrials.gov